*Secondary end point in a 150-day prospective, single-dose, multicentre, randomised, parallel-group, placebo-controlled, double-blind study of 300 patients with moderate to severe glabellar lines treated with ABO (50 Units [U]). Primary end point was response at 30 days. Median time to onset of effect was 2 days.1,2
†Secondary end point across three clinical studies with a total of 1,520 patients treated with Azzalure®, up to 59% of patients reported an onset of effect by Day 2, with a median time to onset of 2–3 days.2-4
‡Onset assessed using patient diary cards (N=120) following glabellar lines treatment in a Phase IV, multicentre, prospective study.3
§Onset assessed using patient diary cards (N=200) following glabellar lines treatment in a placebo-controlled, multicentre, prospective study.2
∥ Onset assessed using patient diary cards (n=1,200) following glabellar lines treatment in a Phase III, open label assessment.4
¶ Secondary end point onset assessed using patient diary cards (N=200) following glabellar lines treatment in a placebo-controlled, multicentre, prospective study.2
**Primary end point in an open-label, multicentre, interventional study which evaluated subject satisfaction following injections of ABO 50 U in the glabellar lines at baseline and 6 months. The primary end point was subject satisfaction at 12 months. Treatment efficacy was assessed using the subject satisfaction questionnaire, FACE-Q Scales (psychological function and appraisal of lines), and the GLSS (scale ranging from 0 [none] to 3 [severe], assessed by both subject [Static 4-point categorical scale] and investigator [4-point photographic scale] at maximum frown) at baseline, 1, 3, 6, 7, 9, and 12 months.3
††Secondary end point in a 150-day prospective, single-dose, multicentre, randomised, parallel-group, placebo-controlled, double-blind study of 300 patients with moderate to severe glabellar lines treated with ABO (50 Units [U]). Primary end point was response at 30 days. At 150 days 45% of patients on Azzalure still experienced a treatment response.2
‡‡AboBoNT-A was first approved for therapeutic use in December 1990 and aesthetic use in April 2009.5-8
References: 1. Galderma (UK) Ltd. Azzalure® Summary of Product Characteristics. February 2024. 2. Monheit GD, et al. Dermatol Surg. 2020;46:61–69. 3. Schlessinger J, et al. Dermatol Surg. 2021;47:504–9. 4. Moy R, et al. Arch Facial Plast Surg. 2009;11:77–83. 5. Brandt F et al. Dermatol Surg. 2009;35:1893–1901. 6. Monheit GD, Pickett A. Aesthet Surg J. 2017;37:S4–11. 7. Kassir R, et al. Dermatol Ther (Heidelb). 2013;3:179–89. 8. Ipsen Biopharmaceuticals, Inc. and Galderma Laboratories, L.P. Dysport® Prescribing Information. September 2023. 9. Galderma. Data on file. MA-52573. More than 100 million Azzalure®/Dysport® treatments delivered in aesthetics indications. June 2022.
As Galderma’s distribution partner, where you are purchasing Galderma Products your personal data may be shared with Galderma and will be stored in accordance with their privacy policy, please see the Galderma privacy policy here to understand how Galderma deal with your personal data.
